Table 3.

Clinical characteristics and first course treatment by cancer site for participants in the Detroit ROCS pilot

AllNon-Hispanic whiteAfrican American
N (%)N (%)N (%)p value*
Breast cancer439174265
AJCC Stage0.550
 I173 (39.4%)69 (39.7%)104 (39.2%)
 II171 (39.0%)69 (39.7%)102 (38.5%)
 III69 (15.7%)29 (16.7%)40 (15.1%)
 IV26 (5.9%)7 (4.0%)19 (7.2%)
Subtype0.007
 ER+ or PR+, HER2+60 (13.7%)26 (14.9%)34 (12.8%)
 ER+ or PR+, HER2261 (59.5%)116 (66.7%)145 (54.7%)
 ER/PR, HER2+26 (5.9%)4 (2.3%)22 (8.3%)
 Triple negative74 (16.9%)22 (12.6%)52 (19.6%)
 Unknown18 (4.1%)6 (3.4%)12 (4.5%)
First course treatment summary0.159
 Lumpectomy alone40 (9.1%)11 (6.3%)29 (10.9%)
 Lumpectomy with radiation262 (59.7%)102 (58.6%)160 (60.4%)
 Mastectomy (with or without adjuvant therapy)116 (26.4%)54 (31.0%)62 (23.4%)
 Radiation, chemotherapy, or hormone21 (4.8%)7 (4.0%)14 (5.3%)
Colorectal cancer1015150
AJCC Stage0.912
 I17 (16.8%)8 (15.7%)9 (18.0%)
 II12 (11.9%)6 (11.8%)6 (12.0%)
 III41 (40.6%)22 (43.1%)19 (38.0%)
 IV31 (30.7%)15 (29.4%)16 (32.0%)
Location0.195
 Distal59 (58.4%)33 (64.7%)26 (52.0%)
 Proximal42 (41.6%)18 (35.3%)24 (48.0%)
First course treatment summary0.748
 Local resection5 (5.0%)3 (5.9%)2 (4.0%)
 Segmental resection alone20 (19.8%)12 (23.5%)8 (16.0%)
 Segmental resection with adjuvant therapy65 (64.4%)31 (60.8%)34 (68.0%)
 Chemotherapy and/or radiotherapy11 (10.9%)5 (9.8%)6 (12.0%)
Lung cancer19710196
AJCC Stage0.018
 I46 (23.4%)19 (18.8%)27 (28.1%)
 II16 (8.1%)7 (6.9%)9 (9.4%)
 III50 (25.4%)22 (21.8%)28 (29.2%)
 IV85 (43.1%)53 (52.5%)32 (33.3%)
Histology0.460
 Non–small cell173 (87.8%)87 (86.1%)86 (89.6%)
 Small cell24 (12.2%)14 (13.9%)10 (10.4%)
First course treatment summary0.056
 Surgery alone35 (17.8%)18 (17.8%)17 (17.7%)
 Surgery with adjuvant treatment23 (11.7%)9 (8.9%)14 (14.6%)
 Radiotherapy alone15 (7.6%)5 (5.0%)10 (10.4%)
 Chemotherapy alone47 (23.9%)32 (31.7%)15 (15.6%)
 Chemo and radiation75 (38.1%)35 (34.7%)40 (41.7%)
 Other2 (1.0%)2 (2.0%)0 (0.0%)
Prostate cancer26388175
AJCC Stage0.017
 I51 (19.4%)16 (18.2%)35 (20.0%)
 II139 (52.9%)39 (44.3%)100 (57.1%)
 III35 (13.3%)13 (14.8%)22 (12.6%)
 IV38 (14.4%)20 (22.7%)18 (10.3%)
Gleason Score0.026
 667 (25.5%)20 (22.7%)47 (26.9%)
 3+468 (25.9%)18 (20.5%)50 (28.6%)
 4+356 (21.3%)17 (19.3%)39 (22.3%)
 8 or higher65 (24.7%)31 (35.2%)34 (19.4%)
 Unknown7 (2.7%)2 (2.3%)5 (2.9%)
First course treatment summary0.019
 None/surveillance43 (16.3%)16 (18.2%)27 (15.4%)
 Radical prostatectomy alone79 (30.0%)37 (42.0%)42 (24.0%)
 Radical prostatectomy plus salvage radiation16 (6.1%)4 (4.5%)12 (6.9%)
 Radiotherapy alone64 (24.3%)13 (14.8%)51 (29.1%)
 Radiotherapy plus hormone therapy46 (17.5%)12 (13.6%)34 (19.4%)
 Hormone therapy alone15 (5.7%)6 (6.8%)9 (5.1%)
  • *Excludes unknown/other category; Cochran–Armitage χ2 reported for ordinal variables (AJCC Stage and Gleason grade) and χ2 for categorical.